OutSense Diagnostics News
7 articles
OutSense to Transform Human Waste into Lifesaving Medical Insights -
Digital health startup OutSense has received an investment from Longevity Venture Partners to pilot its human waste detection technology. The pilot will be conducted in partnership with CommuniCare Family of Companies, a major U.S. healthcare enterprise. OutSense has developed an optical IoT device that can be attached to toilet bowls to analyze human waste for clinical conditions. The device identifies the optical footprint of feces and urine components, sends the data for AI analysis, and provides indications of various diseases. The technology aims to replace manual collection of human waste and enable continuous monitoring and remote diagnosis. OutSense is also conducting clinical trials in Israel and a pilot in Japan. The investment will support product development and preparations for large-scale production.
InvestmentPartners
OutSense expands its Series A funding with new investment from Longevity Venture Partners
OutSense, a company that produces a toilet-based IoT sensor for detecting early signs of illness, has extended its Series A round with a new investment from Longevity Venture Partners. The investment brings the total round to $2.7 million and will be used for product development and preparations for large-scale production. OutSense will be piloting its technology with CommuniCare Family of Companies, a U.S healthcare enterprise. The company is conducting clinical trials in Israel and Japan. The IoT device developed by OutSense can scan human waste and provide early indications of various diseases. The new investment and partnership with a major U.S. healthcare provider signal the potential for early detection of diseases and cost savings in healthcare.
InvestmentPartners
Toilet sensor set to transform colorectal cancer screening
OutSense, a healthcare technology company, has developed an early screening device for colorectal cancer that attaches to the toilet and operates automatically. The IoT sensor scans solid waste for traces of blood, which can be a sign of disease. The results are analyzed in real-time using computer vision algorithms and AI, and any abnormal results are sent to the users smartphone. The technology can also detect dehydration, urinary tract infections, constipation, and diarrhea. OutSense has completed preclinical and clinical studies and raised $2.2 million in a Series A funding round. The company plans to initiate the approval process with the US Food and Drug Administration next year and is looking for strategic partners.
Customers
OutSense's AI looks for life-threatening diseases in your poop - Thebritishjournal Reports - The British Journal
Tech in your toilet: OutSense raises $2.2 million for device that tests poo for health risks
Israel-based OutSense has raised $2.2 million in a series A round led by Peregrine Ventures to develop its IoT technology. The company has created an IoT device that can clip onto any toilet bowl and monitor human health via stool samples, helping to detect diseases such as colorectal cancer, dehydration, urinary tract infections, and constipation or diarrhea. The funds will be used to complete the product design and expand medical trials, with the aim of securing FDA approval. OutSense plans to focus on remote monitoring of the elderly, with the goal of creating the worlds largest database of human waste. The technology also has potential applications in detecting the onset of COVID-19 and personalized care.
InvestmentExpand
Israeli Startup OutSense Will Scan Your Poop to Keep You Healthier
Israeli startup OutSense has developed an IOT device called SA1, a clip-on sensor for toilets that monitors and analyzes stool in real-time. The sensor communicates with a mobile app to provide actionable insights on gastrointestinal wellness, including screening for hidden blood, a tool for colon cancer detection. OutSense aims to replace current lab tests that lack accuracy and require stool handling. The technology has the potential to improve early detection of colorectal cancer, one of the deadliest forms of cancer. The companys growth prospects are positive as it addresses a significant healthcare challenge.
Customers
CICC Hosts Successful Medical Technology Summit
The California Israel Chamber of Commerce (CICC) announced the success of its CiMED 2017 Conference, which showcased innovative Israeli MedTech startups. The conference, held at Oracles Headquarters, attracted top-tier investors, medical professionals, insurance companies, and other players in the healthcare industry. NovellusDx and OutSense were voted the winners of the startup pitch competition. The CICC aims to strengthen commercial ties between Silicon Valley, Israel, and global companies.
Partners
